SCHEDULE: Vanguard Discloses 5.18% Stake in Corvus Pharmaceuticals

The Vanguard Group has reported a 5.18% beneficial ownership stake in Corvus Pharmaceuticals Inc., held as a passive investment.

Summary

• The Vanguard Group reported beneficial ownership of 3,873,482 shares of Corvus Pharmaceuticals Inc. common stock.
• This stake represents 5.18% of the company's outstanding common stock.
• The filing indicates that Vanguard holds these securities in the ordinary course of business and not for the purpose of changing or influencing the control of Corvus Pharmaceuticals Inc.
• Vanguard has shared voting power over 472,993 shares and shared dispositive power over 3,873,482 shares.
• An internal realignment at The Vanguard Group, Inc. on January 12, 2026, means it no longer performs portfolio management services or administers proxy voting, with certain subsidiaries expected to report beneficial ownership separately in the future.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a passive stake, the presence of a major institutional investor like Vanguard can provide a baseline level of institutional interest and liquidity for Corvus Pharmaceuticals Inc.

Positives

• The disclosure of a significant 5.18% stake by a major institutional investor like The Vanguard Group can signal a degree of market confidence or inclusion in broad market indices for Corvus Pharmaceuticals Inc.

Risks

• The Vanguard Group's investment is explicitly passive, meaning they do not intend to influence or change the control of Corvus Pharmaceuticals Inc., which could limit shareholder advocacy from this large holder.
• The internal realignment at Vanguard on January 12, 2026, may lead to disaggregated reporting by its subsidiaries, potentially altering the visibility of the total Vanguard-affiliated ownership in future filings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Corvus Pharmaceuticals Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." Ashley Grim, Head of Global Fund Administration, The Vanguard Group.

Industry Context

StockSavvy.ai notes that The Vanguard Group is one of the world's largest investment management companies, known for its low-cost index funds and ETFs. Their disclosure of a 5.18% passive stake in Corvus Pharmaceuticals Inc. is typical for a company included in broader market indices that Vanguard's funds track, rather than an active strategic investment in the biotechnology sector.

Stakeholder Impact

• Shareholders of Corvus Pharmaceuticals Inc. gain transparency regarding a significant institutional holder, which can contribute to market stability and liquidity.
• The passive nature of Vanguard's investment indicates no immediate intent to influence corporate strategy or governance, which may be viewed differently by various shareholder groups.

Next Steps

• The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following the internal realignment on January 12, 2026.

Key Dates

Keywords

Corvus Pharmaceuticals, Vanguard Group, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Passive Investment, Biotechnology